• Faster delivery and productivity gains available thanks to expanded manufacturing capacity in chromatography resins, filtration, single-use bags and cell culture
• Most major projects completed in Europe and Asia-Pacific, US resins site slated to be up and running in 2028

Cytiva, a Danaher company and global life sciences leader, has completed significant expansion projects in several locations in the United States, Europe, and Asia as part of its ongoing commitment to enhancing delivery for customers developing and manufacturing advanced therapeutics. Set to continue through 2028, these expansions will meet increased customer demand as part of Cytiva’s long-term growth plan and in-region manufacturing strategy, supported by an investment of USD 1.6 billion since 2019.

Customers now benefit from faster delivery across Cytiva’s portfolio, including chromatography resins, filtration, single-use bags and cell culture media.

Pierre-Alain Ruffieux, Chief Operating Officer at Cytiva, says: “A robust supply chain is critical to our customers so they can deliver life-changing therapies to patients around the world. We have increased our global manufacturing capacity, with a focus on in-region for-region, to meet the demands and best serve the customer.”

The latest investments in chromatography resins and filtration include:

• Approximately double production capacity of chromatography resins manufacturing in Uppsala, Sweden with the addition of new factories, new equipment, as well as improved automation capabilities and a new tank farm for solvent storage.
• Investment in chromatography resins reserves in Sweden to support customers with short-term emergency needs.
• Enhanced local supply in North America with the construction of a second resins manufacturing site with approximately 100 full-time associates in Muskegon, Michigan, now. The site is slated to be fully operational with plans to hire about 100 more associates by end of 2028.

Before and after: the Cytiva site in Muskegon, MI. Photos courtesy of Gilbane.

New filtration manufacturing lines in Pensacola, Florida which will increase the site’s production capacity for filter membranes for North America by 20% by August 2025, with its most-ordered products stocked on-the-shelf.

• Upgrades and expansions in filtration manufacturing Fajardo, Puerto Rico, improving capacity by 33%.
• Expanded filtration device manufacturing in lfracombe, UK, improving capacity by 81%.

  Exterior of Ilfracombe

• The start of filtration manufacturing at Cytiva’s Innovation Hub and manufacturing facility in South Korea in 2026 to address increased demand for high-quality filtration solutions in Asia-Pacific.

Cytiva’s latest capacity investments are also expanding “in-region, for region” manufacturing of single-use bags, which enable customers to quickly and efficiently work with and change batches during their processes. Specific developments include the trebling of single-use consumable manufacturing capacity in Beijing, China, doubling of manufacturing capacity in Duncan, South Carolina, and sustained manufacturing capacity in Medemblik, Netherlands.

Cytiva is increasing access to cell culture media in North America by expanding dry powder and liquid media manufacturing capacity in Logan, Utah, for large volumes and adding high-speed bottle filling for small volumes. An expanded staging area for finished goods and a new centralized 10 000 ft² quality control laboratory are already supporting increased manufacturing, with 73 850 ft2 of further expansions to come through 2026.

Ruffieux adds: “In addition to Cytiva’s intense improvement work supported by the Danaher Business System, these capacity expansions demonstrate an unparallelled commitment to helping customers make progress to bring therapies to their patients.”

Cytiva and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

About Cytiva

At Cytiva, a Danaher company, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com

About Danaher

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.